By Denny Jacob
Shares of TG Therapeutics Inc. fell nearly 37% to $8.75 Thursday after the company disclosed in a regulatory filing that the Food and Drug Administration imposed a partial clinical hold on select studies of one of its treatments.
According to the regulatory filing, Chief Executive Michael Weiss told an investor conference that the partial clinical hold wasn't based on based on any new information the company provided but appeared to be based on the same data and concerns that led to a previously announced Oncologic Drug Advisory Committee meeting, which is set to take place in either March or April. No new patients may be enrolled to the select chronic lymphocytic leukemia and non-Hodgkin's lymphoma studies identified by the FDA as a result of the partial hold, he said.
Trading in TG Therapeutics was paused for volatility at 10:21 a.m. ET and resumed five minutes later.
Write to Denny Jacob at email@example.com
(END) Dow Jones Newswires